{"disease":{"id":"high-risk-localised-prostate-carcinoma","name":"high risk localised prostate carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07343349","title":"Addition of Focal Boost to Primary Radiotherapy for Prostate Cancer in 12 or 20 Fractions","phase":"NA","overall_status":"RECRUITING","enrollment_count":1016,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT02160353","title":"Neo-adjuvant Abiraterone Prostate Study","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Cancer Trials Ireland","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}